<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7392210\results\search\drug\results.xml">
  <result pre="Dosage in Current Trials Supportive Evidence Caveats References Remdesivir(2014) Antiviral;" exact="Adenosine" post="nucleotide analogue Acts as an RNA-chain terminator by binding"/>
  <result pre="and safety for the treatment of COVID-19 [34], [52], [53]" exact="Ribavirin" post="(1986) Antiviral; Nucleoside analogue Inhibits viral RNA synthesis and"/>
  <result pre="animal model for SARS-CoV infection Limited data available. [57], [58]" exact="Hydroxychloroquine" post="/ chloroquine (HCQ/CQ) (1955/1934) Antimalarial Block viral entry into"/>
  <result pre="for SARS-CoV infection Limited data available. [57], [58] Hydroxychloroquine /" exact="chloroquine" post="(HCQ/CQ) (1955/1934) Antimalarial Block viral entry into cells by"/>
  <result pre="10.1.1 Antivirals 10.1.1.1 Remdesivir Remdesivir, a monophosphate prodrug of an" exact="adenosine" post="analog, was originally developed to combat the Ebola outbreak"/>
  <result pre="gets rapidly catabolized by the Cytochrome P450 enzyme system) [44]," exact="ritonavir" post="(a CYP3A4 inhibitor) is added to increase its plasma"/>
  <result pre="SARS-CoV [45], it was far less potent than Remdesivir and" exact="Chloroquine" post="in-vitro [46]. In a randomized open-label study of 199"/>
  <result pre="significant benefit in mild and moderate COVID-19 cases [56]. 10.1.1.5" exact="Ribavirin" post="Ribavirin, a guanosine analog prescribed for viral hemorrhagic fever"/>
  <result pre="viral S protein for entry into human cells. In mice," exact="camostat" post="mesylate showed a 60% survival rate following SARS-CoV infection,"/>
  <result pre="COVID-19 are currently underway around the globe. 10.1.3 Antimalarial 10.1.3.1" exact="Hydroxychloroquine" post="/ Chloroquine (HCQ/CQ) These are antimalarial drugs which are"/>
  <result pre="currently underway around the globe. 10.1.3 Antimalarial 10.1.3.1 Hydroxychloroquine /" exact="Chloroquine" post="(HCQ/CQ) These are antimalarial drugs which are also believed"/>
  <result pre="=Â 14) group. All six patients in the HCQ plus" exact="Azithromycin" post="group had significantly better viral clearance [60]. However, six"/>
  <result pre="an increased occurrence of ventricular arrhythmias in patients who received" exact="hydroxychloroquine" post="or chloroquine, when used alone or in conjunction with"/>
  <result pre="on 2541 patients, treatment with HCQ alone and HCQÂ +Â" exact="Azithromycin" post="demonstrated a significant reduction in mortality among hospitalized COVID-19"/>
  <result pre="be effective in preventing COVID-19 after a high-risk exposure [64]." exact="Hydroxychloroquine" post="was discontinued from the RECOVERY trial owing to no"/>
  <result pre="or clinical improvement outcomes [65]. The WHO also discontinued the" exact="Hydroxychloroquine" post="trial arm of the SOLIDARITY trial as it did"/>
  <result pre="thus ineffective in COVID-19 patients requiring mechanical ventilation [71]. 10.2.1.3" exact="Ruxolitinib" post="Ruxolitinib has been found to be effective against inflammatory"/>
  <result pre="ineffective in COVID-19 patients requiring mechanical ventilation [71]. 10.2.1.3 Ruxolitinib" exact="Ruxolitinib" post="has been found to be effective against inflammatory and"/>
  <result pre="promising results in the earlier phases [72]. 10.3 Corticosteroids 10.3.1" exact="Methylprednisolone" post="It is a corticosteroid with potent anti-inflammatory properties which"/>
  <result pre="are expected in November 2020. 10.4.3 Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin," exact="omeprazole" post="These drugs are being trialled to study their cardioprotective"/>
  <result pre="COVID-19: a Prospective, Randomized Controlled Trial Experimental: standard careÂ +Â" exact="Methylprednisolone" post="40Â mg q12h for 5Â daysVSPlacebo Comparator: standard care"/>
  <result pre="lung injury score NCT04291729 Evaluation of Ganovo (Danoprevir) Combined With" exact="Ritonavir" post="in the Treatment of SARS-CoV-2 Infection Experimental: GanovoÂ +Â"/>
  <result pre="Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental: GanovoÂ +Â" exact="ritonavir" post="with or without interferon nebulization Phase 4 Single Group"/>
  <result pre="TimeÂ Frame:Â 14Â daysÂ ] NCT04261517 Efficacy and Safety of" exact="Hydroxychloroquine" post="for Treatment of COVID-19 Experimental: HCQ (400Â mg per"/>
  <result pre="rate. [Â TimeÂ Frame:Â 2Â weeksÂ ] NCT04276688 Lopinavir/ Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment Study group: LPV/r"/>
  <result pre="LPV/r 400Â mg/100Â mg twice daily for 14Â daysÂ +Â" exact="Ribavirin" post="400Â mg twice daily for 14Â days + IF"/>
  <result pre="A Compassionate Use Protocol Experimental: 25Â Âµg/kg of body weight" exact="tirofiban" post="as bolus IV injection (3Â min) followed by continuous"/>
  <result pre="of 75Â mg daily for 30Â days.A loading dose of" exact="clopidogrel" post="300Â mg PO, followed by 75Â mg daily for"/>
  <result pre="] NCT04273321 Efficacy and Safety of Corticosteroids in COVID-19 Experimental:" exact="Methylprednisolone" post="1Â mg/kg/day ivgtt for 7Â days Not Applicable Single"/>
  <result pre="Testing, treatment and prophylaxis of SARS-CoV-2Study 1 â€&quot; Contacts receive" exact="Hydroxychloroquine" post="prophylaxis. Contacts will complete a survey collecting demographic, epidemiological"/>
  <result pre="day 14. Contacts will be offered a prophylactic regimen of" exact="hydroxychloroquine" post="(200Â mg tablets) 800Â mg on day 1, and"/>
  <result pre="3, and 7. Cases will be offered a therapeutic regimen" exact="hydroxychloroquine" post="(200Â mg tablets) 800Â mg on day 1, and"/>
  <result pre="care therapyOseltamivir 75Â mg 12 hourly for 5â€&quot;10Â days and" exact="Hydroxychloroquine" post="400Â mg 12 hourly day âˆ’1 followed by 200Â"/>
  <result pre="negativization NCT04345276 Efficacy and Safety of Ganovo (Danoprevir) Combined With" exact="Ritonavir" post="in the Treatment of SARS-CoV-2 Infection Experimental: DanoprevirÂ +Â"/>
  <result pre="Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental: DanoprevirÂ +Â" exact="Ritonavir" post="groupDanoprevir 100Â mg, one tablet each time, twice per"/>
  <result pre="tablet each time, twice per day, up to 10Â days." exact="Ritonavir" post="100Â mg, one tablet each time, twice per day,"/>
  <result pre="(IVM) 12Â mg /weeklyÂ +Â Hydroxychloroquin (HCQ) 400Â mg/dailyÂ +Â" exact="Azithromycin" post="(AZT) 500Â mg dailyVSNo Intervention: Hydroxychloroquine 400Â mg/dailyÂ +Â"/>
  <result pre="(HCQ) 400Â mg/dailyÂ +Â Azithromycin (AZT) 500Â mg dailyVSNo Intervention:" exact="Hydroxychloroquine" post="400Â mg/dailyÂ +Â azithromycin 500Â mg daily Phase 1"/>
  <result pre="Azithromycin (AZT) 500Â mg dailyVSNo Intervention: Hydroxychloroquine 400Â mg/dailyÂ +Â" exact="azithromycin" post="500Â mg daily Phase 1 Randomized; Double blind 100(â‰¥18)"/>
  <result pre="two arms [Â TimeÂ Frame:Â One-monthÂ ] NCT04376814 Favipiravir Plus" exact="Hydroxychloroquine" post="and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 Experimental: Test GroupIn"/>
  <result pre="Frame:Â One-monthÂ ] NCT04376814 Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus" exact="Hydroxychloroquine" post="in COVID-19 Experimental: Test GroupIn this group, Patients will"/>
  <result pre="times per day for 7Â days, plus 200Â mg of" exact="Hydroxychloroquine" post="two times per day will be given to patients"/>
  <result pre="Patients will be given a stat dose of 400Â mg" exact="Hydroxychloroquine" post="tablets plus 200/50Â mg of Lopinavir/Ritonavirtwo times per day"/>
  <result pre="day 1, 4, 7, 28 after first transfusionÂ ] NCT04342650" exact="Chloroquine" post="Diphosphate in the Prevention of SARS in Covid-19 Infection"/>
  <result pre="donation set.VSControl groupThe control group of COVID-19 patients were given" exact="Hydroxychloroquine" post="400Â mg PO twice per day for 5Â days"/>
  <result pre="400Â mg PO twice per day for 5Â days and" exact="Azithromycin" post="once PO 500Â mg per day for 5Â days."/>
  <result pre="Up to 8Â weeksÂ ] NCT04321278 Safety and Efficacy of" exact="Hydroxychloroquine" post="Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil"/>
  <result pre="weeksÂ ] NCT04321278 Safety and Efficacy of Hydroxychloroquine Associated With" exact="Azithromycin" post="in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Experimental: HydroxychloroquineÂ"/>
  <result pre="Experimental: HydroxychloroquineÂ +Â azithromycinHydroxychloroquine [400Â mg 2Ã—/day, 12/12Â h]Â +Â" exact="azithromycin" post="[500Â mg 1Ã—/day]VSActive Comparator: HydroxychloroquineHydroxychloroquine [400Â mg 2Ã—/day, 12/12Â"/>
  <result pre="status [Â TimeÂ Frame:Â 15Â days after randomizationÂ ] NCT04323527" exact="Chloroquine" post="Diphosphate for the Treatment of Severe Acute Respiratory Syndrome"/>
  <result pre="Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator: Low Dose" exact="Chloroquine" post="Diphosphate (5Â days)Low dose chloroquine group consists of 450Â"/>
  <result pre="(CloroCOVID19) Active Comparator: Low Dose Chloroquine Diphosphate (5Â days)Low dose" exact="chloroquine" post="group consists of 450Â mg bid (3 tablets of"/>
  <result pre="tube in case of orotracheal intubation. VSActive Comparator: High Dose" exact="Chloroquine" post="Diphosphate (10Â days) consists of 600Â mg bid (4"/>
  <result pre="reduced in cancer drug discovery?Expert Opin. Drug Discov.8201336336823373702 34WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="studied in RECOVERY, https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery. Accessed 19 July 2020. 49WHO discontinues" exact="hydroxychloroquine" post="and lopinavir/ritonavir treatment arms for COVID-19, https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 19"/>
  <result pre="modeling and docking studies of TMPRSS2 with experimentally known inhibitors" exact="camostat" post="mesylate, nafamostat and bromhexine hydrochloride to control SARS-Coronavirus-2. (2020)."/>
  <result pre="docking studies of TMPRSS2 with experimentally known inhibitors camostat mesylate," exact="nafamostat" post="and bromhexine hydrochloride to control SARS-Coronavirus-2. (2020). doi:10.26434/chemrxiv.12162360.v1. 58ZhouY.Protease"/>
  <result pre="of TMPRSS2 with experimentally known inhibitors camostat mesylate, nafamostat and" exact="bromhexine" post="hydrochloride to control SARS-Coronavirus-2. (2020). doi:10.26434/chemrxiv.12162360.v1. 58ZhouY.Protease inhibitors targeting"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="non-randomized clinical trialInt. J. Antimicrob. Agents105949202010.1016/j.ijantimicag.2020.105949 61M.G.S. Borba, et al.," exact="Chloroquine" post="diphosphate in two different dosages as adjunctive therapy of"/>
  <result pre="(CloroCovid-19 Study), Infect. Diseases (except HIV/AIDS), (2020). doi:10.1101/2020.04.07.20056424. 62MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  <result pre="Infect. Diseases97202039640332623082 64D.R. Boulware, et al., A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19, N. Engl. J. Med."/>
  <result pre="Med. NEJMoa2016638 (2020). doi:10.1056/NEJMoa2016638. 65No clinical benefit from use of" exact="hydroxychloroquine" post="in hospitalised patients with COVID-19, https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. Accessed 18 July"/>
  <result pre="https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. Accessed 18 July 2020. 66FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
  <result pre="18 July 2020. 66FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
  <result pre="corticosteroids for 2019-nCoV pneumoniaLancet395202068368432122468 75P. Horby, et al., Effect of" exact="dexamethasone" post="in hospitalized patients with COVID-19: preliminary report, Infect. Diseases"/>
 </snippets>
</snippetsTree>
